Partnership

We believe the strength of our stem cell therapy provides us with significant opportunities to expand our product pipeline through innovative collaboration with the right institutions in the field of regenerative medicine. We have collaborations in place with several leading institutions in Malaysia and Australia.

aims-logo
ukm-logo
UPM-logo
monash-logo

Investor

Meluha Life Sciences focused on the development of cellular and gene therapies, including its product candidates Chondrogen and Chondrokin, which are innovative cell therapy products that employ various aspects of developmental platform to treat knee injuries in the scope of orthopaedics, specifically on cartilage damage in the knee.

In the first quarter of 2019, our Phase 1 clinical trial of Chondrogen has met the primary endpoint of a statistically
significant improvement in pain and function after the treatment. Based on the significant data, Meluha Life Sciences
has initiated a MoU with Hospital Universiti Kebangsaan Malaysia (HUKM) to proceed the clinical path forward for
Chondrogen and Chondrokin.

Meluha-Logo-RGB-01

MELUHA THERAPEUTICS SDN BHD
Lot 1G & 2G,
Kompleks Lanai,
No.2, Persiaran Seri Perdana,
62250 Putrajaya, Malaysia.

© Meluha Therapeutics